Jasper Therapeutics, Inc. (NASDAQ:JSPRW) Sees Significant Increase in Short Interest

Jasper Therapeutics, Inc. (NASDAQ:JSPRW) was the recipient of a significant increase in short interest in April. As of April 30th, there was short interest totaling 6,729 shares, an increase of 94.7% from the April 15th total of 3,456 shares. Based on an average trading volume of 14,318 shares, the short-interest ratio is currently 0.5 days.

Jasper Therapeutics Stock Up 13.5%

Shares of Jasper Therapeutics stock traded up $0.00 during trading hours on Friday, hitting $0.02. The company’s stock had a trading volume of 7,989 shares, compared to its average volume of 20,498. Jasper Therapeutics has a 12 month low of $0.01 and a 12 month high of $0.18. The stock has a 50 day moving average of $0.02 and a 200 day moving average of $0.06.

About Jasper Therapeutics

Jasper Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on developing a new generation of cellular therapeutics for severe diseases. The company’s mission centers on harnessing targeted biological agents and engineered cell platforms to improve outcomes in hematopoietic stem cell transplantation, oncology and gene therapies. By advancing novel approaches to conditioning regimens and cell engineering, Jasper aims to address limitations of existing treatments, including toxicity, graft failure and restricted applicability.

The company’s lead candidate, JSP191, is a humanized monoclonal antibody targeting the CD117 receptor on hematopoietic stem cells.